Research-based evidence summarized in this review strongly suggests a crucial role for P2X7 in hematological malignancies (Figure 2B), thus opening the way to exploiting P2X7 blockade or activation as a possible therapeutic strategy in different blood cancers. Here, P2RX7 is linked to hematopoietic and lymphoid system neoplasm.